Exerpts from the publication

Background
U.S. Special Operations Forces Veterans are at increased risk for a variety of mental health problems and cognitive impairment associated with military service. Current treatments are lacking in effectiveness and adherence. Therefore, this study examined psychedelic treatment with ibogaine and 5-methoxy-N,N-dimethyltryptamine for trauma-related psychological and cognitive impairment among U.S. Special Operations Forces Veterans.

Method
We conducted a survey of Veterans who completed a specific psychedelic clinical program in Mexico between 2017 and 2019. Questions probed retrospective reports of mental health and cognitive functioning during the 30 days before and 30 days after treatment.

Results
Results indicated significant and very large reductions in retrospective report of suicidal ideation (p < .001; d = −1.9), cognitive impairment (p < .001; d = −2.8), and symptoms of posttraumatic stress disorder (p < .001; d = −3.6), depression (p < .001; d = −3.7), and anxiety (p < .001; d = −3.1). Results also showed a significant and large increase in retrospective report of psychological flexibility (p < .001; d = 2.9) from before-to-after the psychedelic treatment. Increases in the retrospective report of psychological flexibility were strongly associated with retrospective report of reductions in cognitive impairment, and symptoms of posttraumatic stress disorder, depression, and anxiety (rs range −0.61 to −0.75; p < .001). Additionally, most participants rated the psychedelic experiences as one of the top five personally meaningful (84%), spiritually significant (88%), and psychologically insightful (86%) experiences of their lives.

Read more

The acute effects of classic psychedelics on memory in humans

C. J. Healy
09 Jan 21

A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus

Rafael Vitor Lima da Cruz, Thiago C. Moulin, Lyvia Lintzmaier Petiz, and Richardson N. Leão
2018 Sep 4

Long-term Follow-up of Psilocybin-facilitated Smoking Cessation

Matthew W. Johnson, PhD, Albert Garcia-Romeu, PhD, and Roland R. Griffiths, PhD
2016 Jul 21

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

Thomas Kingsley Brown, Kenneth Alper
2016 Sep

Details